ライフサイエンスコーパス: liver failure

1 n lead to herpes simplex virus-induced acute liver failure.

2 g in patients with paracetamol-induced acute liver failure.

3 hy is a serious neurological complication of liver failure.

4 4 changed mental status, and one death from liver failure.

5 n the neurological complications after acute liver failure.

6 isease-acute liver failure (ALF) and chronic liver failure.

7 tcomes in acute acetaminophen (APAP)-related liver failure.

8 rrounding normal liver, reducing the risk of liver failure.

9 ophen overdose is the leading cause of acute liver failure.

10 re were no cases of hepatic-related death or liver failure.

11 assessment of patients with acute-on-chronic liver failure.

12 in the IDILI caused by drugs that can cause liver failure.

13 d fibrosis and may progress to cirrhosis and liver failure.

14 n is altered on monocytes from patients with liver failure.

15 uding steatosis, cholestasis, cirrhosis, and liver failure.

16 importance of these variants in human acute liver failure.

17 demonstrated in patients with cirrhosis and liver failure.

18 vival in a lethal model of resection-induced liver failure.

19 threatening complications, such as secondary liver failure.

20 considered the effective approaches to treat liver failure.

21 ry and it is the second most common cause of liver failure.

22 drug-induced idiosyncratic liver injury and liver failure.

23 egenerative therapies for APAP-induced acute liver failure.

24 patitis E may lead to life-threatening acute liver failure.

25 out how to select a proper CBT for different liver failure.

26 nalogue (fialuridine [FIAU]) developed acute liver failure.

27 cytes represents a key event in the cause of liver failure.

28 e, a paradigm for glutathione-mediated acute liver failure.

29 ent in sera of 15 of 19 cases of INH-induced liver failure.

30 drug induced liver injury resulting in acute liver failure.

31 tokine assays 12 h after initiation of acute liver failure.

32 in consecutive patients admitted with acute liver failure.

33 herapy (ART) protects against HCV-associated liver failure.

34 de C, and 136.5% (P < .001) in those without liver failure.

35 dentify patients at risk for postresectional liver failure.

36 tients with end-stage liver disease or acute liver failure.

37 tion but also albumin function is reduced in liver failure.

38 motes liver regeneration, thereby preventing liver failure.

39 hepatic fibrosis, cirrhosis, and eventually liver failure.

40 s with decompensated cirrhosis and fulminant liver failure.

41 Group 3 animals declined rapidly, with acute liver failure.

42 onic, acute-on-chronic, or acute cholestatic liver failure.

43 roliferation after hepatectomy, resulting in liver failure.

44 iculum stress, oxidative stress, and finally liver failure.

45 r decompensations including acute-on-chronic liver failure.

46 that lead to generalized infection and acute liver failure.

47 f neurological complications associated with liver failure.

48 ses residual hepatocyte function, leading to liver failure.

49 peutic option to treat posthepatectomy acute liver failure.

50 on was abandoned because of the high risk of liver failure.

51 and ultimately hepatocellular carcinoma and liver failure.

52 diet before azoxymethane (AOM)-induced acute liver failure.

53 e assays showed pronounced features of acute liver failure 12 h after application of acetaminophen (A

54 f 165 children admitted with pediatric acute liver failure, 136 met the inclusion criteria and 45 of

55 The patient died due to fulminant liver failure 14 months later; the histopathological exa

56 with ALF, 20 patients with acute-on-chronic liver failure, 15 patients with cirrhosis with no eviden

57 BCS of unknown origin (2 patients), chronic liver failure (4 patients), and solitary hepatocellular

58 e significant medical comorbidities, such as liver failure (9.9% vs 4.2%; p < 0.001), metastatic canc

59 In patients with acetaminophen-induced acute liver failure, a low serum level of CSF1 was associated

60 Acetaminophen-induced acute liver failure (AALF) is characterized both by activation

61 ntly associated with a higher probability of liver failure according to ISGLS classification (P = .00

62 Fourteen percent of patients developed liver failure according to ISGLS criteria already after

63 was inversely related to the probability of liver failure according to the 50-50 (P = .02) and ISGLS

64 Patients with liver failure according to the 50-50 criteria (n = 3) ha

65 Acute-on-chronic liver failure (ACLF) in cirrhosis is an increasingly rec

66 Acute-on-chronic liver failure (ACLF) in cirrhosis is characterized by ac

67 The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is

68 decompensated cirrhosis and acute-on-chronic liver failure (ACLF) include susceptibility to infection

69 Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cir

70 Acute-on-chronic liver failure (ACLF) is an ailment with high incidence o

71 Acute on chronic liver failure (ACLF) is associated with multisystem orga

72 Acute-on-chronic liver failure (ACLF) is characterized by acute decompens

73 The acute-on-chronic liver failure (ACLF) syndrome is characterized by acute

74 and prognostic criteria of acute-on-chronic liver failure (ACLF) were developed in patients with no

75 Patients were comparable in severity of liver failure, active bleeding at endoscopy, and initial

76 78 patients with acetaminophen-induced acute liver failure admitted to the Royal Infirmary Edinburgh

77 As elevated PVP is associated with liver failure after living donor liver transplantation,

78 can help with the assessment of the risk for liver failure after major liver resection.

79 llected to measure cytokines and a marker of liver failure (alanine aminotransferase); liver tissues

80 alcoholic liver disease (8.3-24.0) and acute liver failure (ALF) (5.9-7.6).

81 as also analyzed by underlying disease-acute liver failure (ALF) and chronic liver failure.

82 n, overwhelming liver damage can cause acute liver failure (ALF) and death without emergent liver tra

83 dults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy

84 Twelve percent of all acute liver failure (ALF) cases are of unknown origin, often t

85 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have defects in innate immune respon

86 BACKGROUND DATA: Patients with severe acute liver failure (ALF) have extreme physiologic dysfunction

87 tamol) poisoning is a leading cause of acute liver failure (ALF) in humans and induces hepatocyte nec

88 Acute liver failure (ALF) in infancy and childhood is a life-t

89 (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries, yet ra

90 ion accuracy of an e-Nose in detecting acute liver failure (ALF) in rats.

91 Medications are a major cause of acute liver failure (ALF) in the United States, but no populat

92 inophen (APAP) is the leading cause of acute liver failure (ALF) in the United States.

93 Acute liver failure (ALF) induced by diffuse metastatic diseas

94 Acute liver failure (ALF) is a devastating clinical syndrome w

95 Acute liver failure (ALF) is a prototypical syndrome of system

96 Acute liver failure (ALF) is a rare syndrome of severe, rapid-

97 Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant morta

98 Mortality of patients with acute liver failure (ALF) is still unacceptably high.

99 Drug-induced and indeterminate acute liver failure (ALF) might be due to an autoimmune-like h

100 s the most suitable source of CBTs for acute liver failure (ALF) or chronic liver failure (CLF) remai

101 op severe acute liver injury (sALI) or acute liver failure (ALF) remain little known.

102 Acute liver failure (ALF) represents a life-threatening situat

103 lity to developing sepsis is common in acute liver failure (ALF) resulting in tissue damage and organ

104 taminophen (APAP, paracetamol)-induced acute liver failure (ALF) showed significant differences in th

105 LPS) and concanavalin A (ConA)-induced acute liver failure (ALF), but the mechanism by which FK866 af

106 y models in mice, and in patients with acute liver failure (ALF).

107 rious in pregnancy and could result in acute liver failure (ALF).

108 , is used widely to determine risk for acute liver failure (ALF).

109 en (APAP) overdose is a major cause of acute liver failure (ALF).

110 and potentially fatal complication of acute liver failure (ALF).

111 inophen toxicity is a leading cause of acute liver failure (ALF).

112 r support device, may be beneficial in acute liver failure (ALF).

113 tension and mortality in patients with acute liver failure (ALF).

114 f patients with acute liver injury and acute liver failure (ALI/ALF).

115 eveloped hepatocellular carcinoma, and 1 had liver failure, all of whom were in the obese group.

116 f NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding di

117 c injury other than hepatic-related death or liver failure among duloxetine initiators compared to ve

118 dden cardiac deaths and no deaths related to liver failure among patients who received treatment with

119 Importantly, 1 patient developed liver failure and 2 patients developed protein-caloric m

120 nderstanding of the processes culminating in liver failure and cancer and to prioritize vaccine candi

121 n people worldwide and is a leading cause of liver failure and cancer.

122 AT can be a promising therapy to treat acute liver failure and clinical studies to explore this treat

123 24 patients with acetaminophen-induced acute liver failure and compared with 10 healthy controls.

124 use interruption of chemotherapy and lead to liver failure and death.

125 rug screening and therapeutic strategies for liver failure and diabetes.

126 omising alternative therapeutic approach for liver failure and different cell sources have been teste

127 into mice with concanavalin-A-induced acute liver failure and fatal metabolic liver disease due to f

128 ic consequences to the graft including acute liver failure and graft loss.

129 Mice given SR9009 developed less-severe liver failure and had longer survival times than mice gi

130 etaminophen (APAP) overdose results in acute liver failure and has limited treatment options.

131 ple worldwide and is a major risk factor for liver failure and hepatocellular carcinoma.

132 developed clinical and serologic evidence of liver failure and lactic acidosis.

133 V) infection is one of the leading causes of liver failure and liver cancer, affecting around 3% of t

134 tion to prevent progress of life-threatening liver failure and liver transplantation in patients with

135 m survival of patients with acute-on-chronic liver failure and multiple organ failure.

136 yperammonemia animal models, including acute liver failure and ornithine transcarbamylase deficiency,

137 ar dedifferentiation likely mediate terminal liver failure and suggest reinstatement of this network

138 n overdose is the most common cause of acute liver failure and the leading cause of chronic liver dam

139 s and cirrhosis, which eventually results in liver failure and the need for liver transplantation.

140 the only definitive treatment for end stage liver failure and the shortage of donor organs severely

141 ntation (LT) between patients with fulminant liver failure and those with cirrhosis and severe hepati

142 isorder of copper accumulation that leads to liver failure and/or neurological deficits.

143 world's population and is a leading cause of liver failures and the need for liver transplantation.

144 e hemorrhagic fever, neurological disorders, liver failure, and blindness, which could collectively b

145 e events including recurrence of HCC, death, liver failure, and complications of cirrhosis were recor

146 tment prevented hepatocyte death, subsequent liver failure, and death in the rodent model.

147 haracterised by florid hepatic inflammation, liver failure, and death within 28 days in 35% of patien

148 an lead to severe acute hepatitis, fulminant liver failure, and death.

149 e survival in patients with acute-on-chronic liver failure, and erythropoietin promoted hepatic regen

150 Hypoxemia is a feared complication of acute liver failure, and high oxygen requirements will frequen

151 Two individuals died of liver failure, and one individual was successfully treat

152 ical record-confirmed hepatic-related death, liver failure, and other clinically significant hepatic

153 generalized infections and subsequent acute liver failure are less well understood.

154 Urea cycle defects and acute or chronic liver failure are linked to systemic hyperammonemia and

155 acute respiratory distress syndrome in acute liver failure are scant and hypoxemia being a commonly e

156 ; RR, 0.35 [95% CI, 0.16-0.75]; P = .006) or liver failure (ARR, 0.046 [95% CI, 0.008-0.088]; RR, 0.2

157 Recognition of acute-on-chronic liver failure as a clinically and pathophysiologically d

158 e use of ISGLS definition of posthepatectomy liver failure as early predictor of outcome.

159 9 expression in acetaminophen-induced acute liver failure being mediated both by circulating endogen

160 There were no intergroup differences in liver failure (both 7.1%) and 90-day morbimortality.

161 previously been implicated in cirrhosis and liver failure but not in isolated portal hypertension.

162 The greatest cause of death was liver failure, but attempted anti-hepatitis C virus ther

163 tly the only effective therapy for fulminant liver failure, but its use is limited by the scarcity of

164 Treatment of acute liver failure by cell transplantation is hindered by a s

165 21 may thus be therapeutically beneficial in liver failure by preventing apoptosis and by inducing li

166 chronic liver failure grades 1-3 and Chronic Liver Failure-C-Organ Failure liver subscore equals to 3

167 reased kidney, brain, or coagulation Chronic Liver Failure-C-Organ Failure subscores.

168 Life-threatening acute liver failure can be triggered by a variety of factors,

169 We describe a case of acute liver failure caused by echovirus 25 (E25) in a previous

170 first report of acute hepatic necrosis with liver failure caused by Salmonella in a dog.

171 ng survival, while in patients with advanced liver failure (Child B/C), EVL alone carries an increase

172 Failure dataset with adoption of the Chronic Liver Failure-classification resulted in similar finding

173 ult patients with PCLD to those with chronic liver failure (CLF) and hepatocellular carcinoma.

174 abase on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on

175 BTs for acute liver failure (ALF) or chronic liver failure (CLF) remains unclear.

176 the prospective multicenter European Chronic Liver Failure (CLIF) ACLF in Cirrhosis study.

177 Acute-on-chronic liver failure combines an acute deterioration in liver f

178 oncentrations in acetaminophen-induced acute liver failure compared with controls (p < 0.05).

179 ll patients with acetaminophen-induced acute liver failure compared with healthy controls (p < 0.0001

180 A new diagnostic score, the Chronic Liver Failure Consortium (CLIF-C) organ failure score, h

181 oimmune hepatitis) or patients without acute liver failure (controls) collected from a DILI Biobank i

182 in 7.6% of cases; 40% of these had nonacute liver failure courses.

183 by applying the recently introduced Chronic Liver Failure-criteria.

184 In a porcine model of severe liver failure, damage was assured in all animals by surg

185 s analysis and combined outcomes of death or liver failure (defined as MELD score >/=30).

186 nial pressure monitor in acetaminophen acute liver failure did not confer a significant 21-day mortal

187 The search terms were "liver injury," "liver failure," "DILI," "hepatitis," "hepatotoxicity," "

188 ve therapy for toxic ingestion or idiopathic liver failure (DT) in a level 1 trauma center and large

189 rates of up to 50% have been reported after liver failure due to drug-induced hepatotoxicity and cer

190 nd are not an associated finding in neonatal liver failure due to other causes.

191 e in a well-established mouse model of acute liver failure during septic shock.

192 e, outcomes, and prognostic factors of early liver failure (ELF) after transjugular intrahepatic port

193 bilize the lost metabolic function for acute liver failure, end-stage and congenital liver diseases,

194 analysis in individuals with acute infantile liver failure, especially if triggered by fever.

195 ic steatohepatitis can lead to cirrhosis and liver failure for which there are currently no approved

196 Liver failure from any number of sources (e.g. viral inf

197 ith multiple organ failure (acute-on-chronic liver failure grade 2-3).

198 First, 101 patients with acute-on-chronic liver failure grades 1-3 and Chronic Liver Failure-C-Org

199 d severe laboratory abnormalities, and acute liver failure has been reported (Table ).

200 er, predicting whether or not a patient with liver failure has reversible kidney disease, and therefo

201 ion is a global health problem, resulting in liver failure, hepatocellular carcinoma, and liver-relat

202 long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-relat

203 er fibrosis leads to portal hypertension and liver failure; however, the mechanisms leading to fibros

204 rvival in infection-related acute-on-chronic liver failure (I-ACLF) derived from multicenter studies

205 nto an immune-deficient mouse model of human liver failure, iMPC-Heps proliferated extensively and ac

206 cause for 90-day mortality was postoperative liver failure in 75% of patients.

207 Cl4-treated rats; and rapidly reversed fatal liver failure in CCl4-treated animals by restoring disea

208 constitutes a safe and efficient therapy for liver failure in children.

209 cirrhosis in the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study.

210 o presented with recurrent episodes of acute liver failure in early infancy and are affected by cereb

211 ndoPC-derived hepatocytes are able to rescue liver failure in Fah(-/-)Rag2(-/-) mice after transplant

212 cause it is among the common causes of acute liver failure in intensive care units and in light of it

213 interact to increase the risk of death from liver failure in men.

214 resent a therapeutic strategy to treat acute liver failure in mice.

215 th fibrosis and steatosis, leading in one to liver failure in the course of infections.

216 meliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provide new

217 TS13 activity is associated with progressive liver failure in the patient cohort, which might be attr

218 is a major cause of hepatotoxicity and acute liver failure in the U.S., but the pathophysiology is in

219 injury and the most frequent cause of acute liver failure in the Western world.

220 inophen (APAP) is the leading cause of acute liver failure in the Western world.

221 model of resistance to Fas receptor-mediated liver failure in the wild-derived MSM strain, compared w

222 curred (2.7%): hemothorax in one patient and liver failure in two, with major portal-systemic shunts.

223 ct from death in a lethal model of fulminant liver failure induced by intraperitoneal injection of D-

224 Acute liver failure initiates a sterile inflammatory response

225 anial pressure monitored patients with acute liver failure, intracranial hypertension is commonly obs

226 ss that occurs after liver injury, but acute liver failure is a complex and fatal disease which is di

227 Acute-on-chronic liver failure is associated with numerous consecutive or

228 y benefit, whereas in nonacetaminophen acute liver failure, it may be associated with worse outcomes.

229 atients with WD who have progressed to acute liver failure, leaving liver transplantation as the only

230 Liver failure (LF) is associated with prolonged hospital

231 Patients with paracetamol-induced acute liver failure managed at intensive care units in the UK

232 The rate of continued progression to liver failure may be proportional to the degree of under

233 These data suggest that fulminant liver failure may potentially benefit from treatment wit

234 ria, RLE was 112.5% in patients with grade A liver failure (n = 20), 88.4% in patients with grade B (

235 is without decompensation (n = 17), or acute liver failure (n = 23).

236 cipients died of recurrent hemorrhage (n=2), liver failure (n=1), and pneumonia (n=1).

237 Acute liver failure not caused by paracetamol was associated w

238 tions classified as grade III or higher were liver failures occurring in patients with Child-Pugh cla

239 rtment syndrome must be suspected when acute liver failure occurs in patients with subcapsular hemato

240 was increased in acetaminophen-induced acute liver failure on day 1 compared with healthy controls (p

241 an excellent outcome for patients with acute liver failure or complications of end-stage liver diseas

242 njury has been described involving fulminant liver failure or death.

243 al alternatives to organ transplantation for liver failure or dysfunction but are compromised by inef

244 ack in acute intermittent porphyria or acute liver failure or end-stage chronic liver disease in eryt

245 failure, whether arising directly from acute liver failure or from decompensated chronic liver diseas

246 No patient with reactivation experienced liver failure or liver-related death within 36 weeks aft

247 There were no signs of liver failure or small-for-size syndrome.

248 in patients with acetaminophen-induced acute liver failure (p = 0.042) at the time of liver transplan

249 Pediatric acute liver failure (PALF) is a potentially devastating condit

250 een children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in non-AP

251 l pressure monitoring in patients with acute liver failure, patient selection and ancillary assessmen

252 Retrospective analysis of acute-on-chronic liver failure patients receiving either standard medical

253 Acute liver failure patients receiving mechanical ventilation

254 Two hundred acute liver failure patients were admitted during the study pe

255 In chronic liver failure patients with sustained fibrosis, excessiv

256 a risk of secondary poisoning especially in liver-failure patients.

257 phases of human acetaminophen-induced acute liver failure, peaking on day 1 of hospital admission, a

258 the influence of acetaminophen-induced acute liver failure plasma and endogenous DNA on Toll-like rec

259 e incubated with acetaminophen-induced acute liver failure plasma with and without deoxyribonuclease-

260 stimulation with acetaminophen-induced acute liver failure plasma, which was abrogated by preincubati

261 In drug-induced acute liver failure, plasma levels correlate with outcome.

262 the critical period for survival after acute liver failure, providing promising clues of integration

263 onditions are known to cause recurrent acute liver failure (RALF), and in about 50% of cases, the und

264 Acute liver failure remains a critical clinical condition, wit

265 extensive liver resection, post-hepatectomy liver failure remains one of the most lethal complicatio

266 r detrimental in acetaminophen-induced acute liver failure remains unknown.

267 transplantation in paracetamol-induced acute liver failure require re-evaluation.

268 b again, and her cancer-related symptoms and liver failure resolved.

269 s with organ failure (defined by the chronic liver failure-sequential organ failure assessment [CLIF-

270 tion of hiPSC-EB-HLC in a rat model of acute liver failure significantly prolonged the mean survival

271 , and drug-induced ALF patients in the Acute Liver Failure Study Group from 1998-2007.

272 , who met the criteria defined by the "Acute Liver Failure Study Group Germany".

273 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686

274 t assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014).

275 les of 681 adults enrolled in the U.S. Acute Liver Failure Study Group were tested for anti-HEV immun

276 Acute Liver Failure Study Group.

277 Well-established preclinical models of acute liver failure such as the Jo2 FAS/CD95 activating model

278 hepatitis (AH) is a syndrome of jaundice and liver failure that occurs in a minority of heavy consume

279 lines to a Fah(-/-) Il2rg(-/-) rat model of liver failure, the rat liver stem cells engrafted into t

280 er is a central regulator of metabolism, and liver failure thus constitutes a major health burden.

281 or patients with acetaminophen-induced acute liver failure to develop sepsis, which may culminate in

282 t of patients with paracetamol-induced acute liver failure to identify those needing emergency liver

283 critically ill children with pediatric acute liver failure to provide stability and bridge to transpl

284 um ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin >/=12 mg/dL) at ACLF diag

285 iprazole for MI, and telithromycin for acute liver failure) using Medicaid Analytic eXtracts (from al

286 serious liver-related adverse events such as liver failure, variceal bleeding, serious infections, sp

287 The risks of death and progression to liver failure varied greatly by fibrosis stage.

288 neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammatory path

289 Acute liver failure was induced in BALB/c mice by a toxic dose

290 renal replacement therapy in pediatric acute liver failure were changed in 2011 following preliminary

291 Usual causes of acute liver failure were excluded, all drugs were stopped and

292 Children with pediatric acute liver failure were managed according to a set protocol.

293 ht patients with acetaminophen-induced acute liver failure were recruited.

294 Peak levels in patients with acute liver failure were seen at admission then fell significa

295 ce of lung injury is relatively low in acute liver failure, where 21% fulfilled acute respiratory dis

296 Liver failure, whether arising directly from acute liver

297 Among children with pediatric acute liver failure who did not receive a liver transplant, us

298 report a case of an adult male with EPP and liver failure who successfully underwent a sequential li

299 injury (DILI) is an important cause of acute liver failure, with limited therapeutic options.

300 Unfortunately, liver failure worsened dramatically while patient develo